UK, Oxagen Completes £16M Series C Financing Round
Oxagen Limited, a Milton Park, UK-based drug discovery and development company specializing in inflammation, completed a £16m ($26.7m) Series C round led by Novartis Venture Funds. Existing investors including MPM Capital, SV Life Sciences, Advent Ventures, Bessemer Venture Partners, Omega, Abingworth, IBT, Red Abbey and The Wellcome Trust, participated in the round. The proceeds will […]